Different grades of gynaecomastia help clinicians describe the extent of male breast tissue enlargement and guide appropriate management. Gynaecomastia — the benign proliferation of glandular breast tissue in males — affects men at various life stages, from adolescence through to older age. Grading systems such as the Simon classification and Rohrich classification categorise the condition by tissue volume, skin redundancy, and ptosis, enabling consistent clinical communication and informed treatment planning. Understanding how grades differ is essential for patients and clinicians alike, supporting decisions around watchful waiting, medical therapy, or surgical intervention.

What Is Gynaecomastia and Why Does Grading Matter?

Gynaecomastia is benign glandular breast enlargement in males caused by oestrogen–androgen imbalance; grading matters because it standardises clinical communication, sets patient expectations, and guides surgical planning.

Have any more questions about this? Message our pharmaceutical team to get more info →

Gynaecomastia is the benign enlargement of glandular breast tissue in males, resulting from an imbalance between oestrogen and androgen activity in breast tissue. It is distinct from pseudogynaecomastia, which refers to fatty tissue accumulation without true glandular proliferation — a distinction that has direct implications for management. Gynaecomastia can affect one or both breasts and may present at any age, though it is particularly common during puberty, middle age, and in older men.

Understanding the different grades of gynaecomastia is clinically important because grading provides a consistent framework for describing the extent of tissue involvement, supporting communication between clinicians, setting realistic patient expectations, and guiding surgical planning when intervention is required. It is important to note, however, that grading alone is not a reliable predictor of whether gynaecomastia will resolve spontaneously — the likelihood of resolution depends more on the underlying cause and the duration of the condition than on grade. Without a standardised grading framework, treatment decisions risk being inconsistent or disproportionate to the degree of tissue involvement.

The most widely referenced classification system in clinical practice is the Simon grading scale, though the Rohrich classification is also used, particularly in surgical planning. Both systems categorise gynaecomastia based on the volume of breast tissue, the degree of skin excess, and the presence of ptosis (drooping). Grading is not merely academic — it forms part of a structured, patient-centred approach to a condition that, while benign, can cause significant psychological distress, including reduced self-esteem and social withdrawal.

Further information is available from the NHS (Breast enlargement in men) and NICE Clinical Knowledge Summary (CKS): Gynaecomastia.

The Main Grades of Gynaecomastia Explained

The Simon classification defines four grades: Grade I (minor subareolar enlargement, no skin excess) through to Grade III (marked enlargement with skin redundancy and ptosis resembling female breast morphology).

The Simon classification divides gynaecomastia into four grades based on clinical presentation:

• Grade I (Minor enlargement, no skin excess): A small but palpable mound of glandular tissue beneath the areola, with no redundant skin. The breast contour may appear slightly raised but is not prominently visible through clothing. This grade is common in adolescent boys; pubertal gynaecomastia typically resolves spontaneously within 6 to 24 months, though resolution depends primarily on the underlying cause and duration rather than grade alone.

• Grade IIa (Moderate enlargement, no skin excess): More noticeable breast tissue that extends beyond the areolar margin, but the overlying skin remains taut and well-fitted to the underlying tissue. The chest contour is visibly altered, particularly in fitted clothing.

• Grade IIb (Moderate enlargement with minor skin excess): Similar tissue volume to Grade IIa, but with a small degree of skin redundancy beginning to develop. Higher grades such as this often reflect longer-standing disease, which makes spontaneous resolution less likely and surgical intervention more probable — though the decision to treat depends on duration, underlying cause, and patient preference rather than grade alone.

• Grade III (Marked enlargement with skin excess and ptosis): Significant breast tissue with considerable skin redundancy and drooping, resembling a female breast morphology. This grade is most commonly seen in older men, those with significant weight fluctuation, or individuals with longstanding untreated gynaecomastia.

The Rohrich classification further subdivides these categories and incorporates ptosis grading, which is particularly useful when planning surgical correction. It is worth noting that grading systems describe anatomical findings rather than aetiology — the underlying cause (hormonal, drug-induced, idiopathic) must be assessed separately. Both systems are complementary tools rather than standalone diagnostic instruments.

See also: NICE CKS: Gynaecomastia; BAAPS/BAPRAS guidance on gynaecomastia surgery.

How Doctors in the UK Assess and Diagnose Each Grade

UK GPs assess gynaecomastia grade through clinical inspection and palpation, supported by blood tests, imaging, and testicular examination; urgent 2-week wait referral is required if malignancy cannot be excluded.

In the UK, assessment of gynaecomastia typically begins in primary care. A GP will take a thorough history, including onset and duration of breast enlargement, medication use (including prescribed, over-the-counter, and herbal preparations), recreational drug and anabolic steroid use, and any symptoms suggestive of an underlying systemic condition such as liver disease, hypogonadism, or hyperthyroidism. Physical examination includes careful palpation to distinguish true glandular tissue — which feels firm and disc-like beneath the nipple — from soft, diffuse fatty tissue consistent with pseudogynaecomastia, as well as testicular examination in all cases to identify masses or atrophy.

Grading is determined clinically through inspection and palpation, assessing tissue volume, skin redundancy, and the presence of ptosis. Investigations are guided by clinical suspicion and may include:

• Blood tests: Serum testosterone, luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol, prolactin, thyroid function tests, liver function tests, and renal function. Serum beta-hCG should be measured where a testicular or hCG-secreting tumour is suspected; alpha-fetoprotein (AFP) may also be considered if a germ-cell tumour is a possibility.

• Imaging: Referral for breast ultrasound (with or without mammography) is appropriate where there is a suspicious breast mass, nipple or skin changes, or diagnostic uncertainty — not simply on the basis of unilateral presentation alone. Testicular ultrasound is indicated if a testicular tumour is suspected.

• Karyotyping: Considered if Klinefelter syndrome is suspected.

In line with NICE NG12 (Suspected cancer: recognition and referral), an urgent 2-week wait referral to a breast clinic should be considered for men presenting with suspicious features such as a hard, irregular, or fixed subareolar mass; unilateral nipple retraction or discharge (particularly if bloodstained); skin changes (including dimpling, ulceration, or peau d'orange); or palpable axillary lymphadenopathy. Male breast cancer is rare, but these features warrant prompt specialist assessment to exclude it.

Referral routes should be directed appropriately: breast clinic for suspicious breast findings; endocrinology for hormonal evaluation; urology for suspected testicular pathology; and genetics or endocrinology where Klinefelter syndrome is suspected. Accurate grading at this stage ensures that onward referrals are well-informed and directed to the most appropriate specialist.

References: NICE CKS: Gynaecomastia; NICE NG12: Suspected cancer — recognition and referral; British Society of Breast Radiology guidance on male breast imaging.

Treatment Options Based on Gynaecomastia Grade

Treatment ranges from watchful waiting and conservative measures in Grade I to surgical excision in higher grades; medical therapy with tamoxifen is most effective in the early proliferative phase under specialist supervision.

Management of gynaecomastia is tailored to the grade, duration, underlying cause, and the degree of psychological impact on the patient. Not all grades require active treatment — in many cases, particularly Grade I in adolescents, a period of watchful waiting is appropriate, with reassurance that spontaneous resolution is likely within 6 to 24 months.

Conservative measures should be considered first in all cases and include:

• Reviewing and, where clinically appropriate, withdrawing or substituting causative medications (such as spironolactone, antipsychotics, or anabolic steroids)

• Weight management if overweight, as adipose tissue increases peripheral aromatisation of androgens to oestrogens

• Reducing alcohol intake and stopping anabolic steroid or recreational drug use

Medical management is most effective in the early, proliferative phase of gynaecomastia (typically within the first six to twelve months), before fibrous stromal tissue replaces active glandular tissue. Options include:

• Tamoxifen (off-label use): An oestrogen receptor modulator that has demonstrated efficacy in reducing breast volume in Grades I and IIa, particularly in adolescents and men with drug-induced gynaecomastia. Tamoxifen use in this context is off-label and should generally be initiated by or under the supervision of a specialist. Prescribers and patients should refer to the current BNF entry and the MHRA/EMC Summary of Product Characteristics (SmPC) for full prescribing information, contraindications, and monitoring requirements.

• Aromatase inhibitors (e.g., anastrozole): May be considered in selected cases under specialist supervision; however, the evidence base is limited and aromatase inhibitors are not routinely recommended for gynaecomastia. Their use should be guided by a specialist with reference to the BNF and relevant SmPC.

• Addressing the underlying cause: Withdrawing or substituting causative medications can lead to regression in early-grade cases.

If you are taking any medication for gynaecomastia and experience unexpected side effects, please report these via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Surgical management is often considered for persistent gynaecomastia where medical therapy has not been effective, where fibrosis has become established, or where there is significant skin excess — features more commonly associated with higher grades (IIb and III) and longer duration. The decision to proceed with surgery depends on tissue composition, duration, symptoms, and patient goals, rather than grade alone. Surgical options include:

• Liposuction: Suitable where fatty tissue predominates

• Subcutaneous mastectomy (glandular excision): Required when firm glandular tissue is present

• Skin excision with or without nipple repositioning: Necessary in Grade III to address significant ptosis and skin redundancy

Surgical correction for gynaecomastia is not routinely funded on the NHS. Funding criteria vary by local Integrated Care Board (ICB) policy; in many areas, an Individual Funding Request (IFR) is required, supported by documented evidence of significant functional or psychological impact. Patients should seek clarification from their GP or referral team regarding local funding arrangements. Patients should also be counselled about realistic outcomes and potential complications, including scarring, asymmetry, and changes in nipple sensation.

References: NICE CKS: Gynaecomastia; BNF: Tamoxifen; Anastrozole; MHRA/EMC SmPCs: Tamoxifen; Anastrozole; local ICB/EBI policies on gynaecomastia surgery; BAAPS/BAPRAS guidance on gynaecomastia surgery.

When to Seek Medical Advice on the NHS

Men should see their GP if breast enlargement persists beyond three months or causes distress; hard irregular masses, nipple changes, skin changes, or axillary lymphadenopathy require urgent review under NICE NG12.

Many men and adolescents feel embarrassed about gynaecomastia and delay seeking help, yet early assessment is important both to identify any underlying cause and to maximise the effectiveness of non-surgical treatment. As a general guide, anyone who notices persistent breast enlargement lasting more than three months, or that is causing discomfort or distress, should book an appointment with their GP.

Certain features should prompt prompt or urgent medical review:

• A hard, irregular, or fixed subareolar mass

• Nipple retraction or discharge, especially if unilateral or bloodstained

• Skin changes such as dimpling, ulceration, or peau d'orange

• Palpable axillary lymph nodes

• Rapid onset or rapid progression of breast tissue growth

• Associated symptoms such as testicular pain or swelling, unexplained weight loss, or fatigue

• Breast pain or tenderness that is persistent or worsening

These features may indicate an underlying condition requiring further investigation. In line with NICE NG12, an urgent referral via the 2-week wait (suspected cancer) pathway should be considered where any of the above suspicious features are present and malignancy cannot be excluded on clinical grounds. Male breast cancer is rare, but prompt assessment is important when these features are identified.

For adolescents, parents and young people should be reassured that pubertal gynaecomastia is common and typically resolves within 6 to 24 months. A GP review is still worthwhile to confirm the diagnosis and rule out pathological causes. Further investigation is advisable if gynaecomastia is prepubertal, persistent beyond 24 months, progressive, associated with systemic symptoms, or potentially medication-induced.

For adult men, particularly those over 40, a proactive approach to assessment is advisable. Regardless of grade, if gynaecomastia is causing significant psychological distress — including anxiety, depression, or avoidance of social or physical activities — this should be communicated clearly to the GP, as it may support a referral for further management or psychological support through NHS services.

References: NICE NG12: Suspected cancer — recognition and referral; NHS: Breast enlargement in men (gynaecomastia); NICE CKS: Gynaecomastia.

Frequently Asked Questions